A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback